Witkin J M, Dijkstra D, Levant B, Akunne H C, Zapata A, Peters S, Shannon H E, Gasior M
Neuroscience Discovery Research, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285-0501, USA.
J Pharmacol Exp Ther. 2004 Mar;308(3):957-64. doi: 10.1124/jpet.103.059980. Epub 2004 Jan 7.
Cocaine abuse is a public health concern with seizures and death being one consequence of overdose. In the present study, dopamine D(3/)D(2) receptor agonists dose dependently and completely prevented the convulsant and lethal effects of cocaine. The D(3)-preferring agonists R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol) [(+)-PD 128,907], (+)-7-hydroxy-dipropylaminotetralin, and the mixed D(3/)D(2) agonists quinpirole and quinelorane were all effective against cocaine toxicity in mice. The anticonvulsant effects of these compounds occurred at doses below those that produced motor impairment as assessed in the inverted screen test. Protection against the convulsant effects of the selective dopamine uptake inhibitor 1-[2-[bis(4-fluorophenyl)methoxy] ethyl]-4-[3-phenyl-propyl]piperazine (GBR 12909) was also conferred by (+)-PD 128,907. The possible selectivity of the effects of (+)-PD 128,907 (3 mg/kg) for these dopaminergic compounds was demonstrated by its general lack of protective efficacy against a host of convulsants acting through other neural mechanisms [pentylenetetrazol, (+)-bicuculline, and picrotoxin, 4-aminopyridine, and t-butylbiclyclophosphoorothionate, N-methyl-d-aspartate, kainate, pilocarpine, nicotine, strychnine, aminophylline, threshold electric shock, and 6-Hz electrical stimulation]. Direct and correlational evidence suggests that these effects were mediated by D(3) receptors. Protection was stereospecific and reversible by an antagonist of D(3) receptors [3-[4[1-(4-[2[4-(3-diethyamino-propoxy)-phenyl]-benzoimidazol-l-yl]-butyl)-1H-benzoimidazol-2-yl]-phenoxy]-propyl)-diethyl-amine; PD 58491] but not D(2) receptors [3[[4-(4-chlorophenyl)-4 hydroxypipeidin-1-yl]methyl-1H-indole; L-741,626]. Anticonvulsant potencies were positively associated with potencies in a functional assay of D(3) but not D(2) receptor function. Together, these findings suggest that the prevention of cocaine convulsions and lethality by (+)-PD 128,907 may be due to D(3) receptor-mediated events.
可卡因滥用是一个公共卫生问题,癫痫发作和死亡是过量使用可卡因的后果之一。在本研究中,多巴胺D(3)/D(2)受体激动剂呈剂量依赖性地完全预防了可卡因的惊厥和致死作用。选择性D(3)受体激动剂R-(+)-反式-3,4a,10b-四氢-4-丙基-2H,5H-[1]苯并吡喃并[4,3-b]-1,4-恶嗪-9-醇[(+)-PD 128,907]、(+)-7-羟基-二丙基氨基四氢萘,以及混合D(3)/D(2)受体激动剂喹吡罗和喹氯烷对小鼠可卡因毒性均有作用。在倒屏试验中评估发现,这些化合物的抗惊厥作用发生在产生运动障碍剂量以下。(+)-PD 128,907对选择性多巴胺摄取抑制剂1-[2-[双(4-氟苯基)甲氧基]乙基]-4-[3-苯基丙基]哌嗪(GBR 12909)的惊厥作用也有保护作用。(+)-PD 128,907(3mg/kg)对这些多巴胺能化合物作用的可能选择性表现为,其对一系列通过其他神经机制起作用的惊厥剂[戊四氮、(+)-荷包牡丹碱、苦味毒、4-氨基吡啶、叔丁基双环磷酰硫代胆碱、N-甲基-D-天冬氨酸、红藻氨酸、毛果芸香碱、尼古丁、士的宁、氨茶碱、阈下电击和6Hz电刺激]普遍缺乏保护效力。直接和相关证据表明,这些作用是由D(3)受体介导的。D(3)受体拮抗剂[3-[4-[1-(4-[2-[4-(3-二乙氨基丙氧基)-苯基]-苯并咪唑-1-基]-丁基)-1H-苯并咪唑-2-基]-苯氧基]-丙基)-二乙胺;PD 58491]可使保护作用具有立体特异性且可逆,但D(2)受体拮抗剂[3-[[4-(4-氯苯基)-4-羟基哌啶-1-基]甲基-1H-吲哚;L-741,626]则不能。抗惊厥效力与D(3)受体功能的功能测定效力呈正相关,而与D(2)受体功能无关。总之,这些发现表明,(+)-PD 128,907预防可卡因惊厥和致死作用可能是由于D(3)受体介导的事件。
J Pharmacol Exp Ther. 2005-7
Eur J Pharmacol. 1998-4-24
J Pharmacol Exp Ther. 1997-10
Eur J Pharmacol. 1998-8-14
J Pharmacol Exp Ther. 1995-12
Eur J Pharmacol. 1999-10-27
Neuropharmacology. 2024-10-1
Exp Clin Psychopharmacol. 2011-10
J Pharmacol Exp Ther. 2005-7